Because of the fact that CFTR modulators improve the function of the CFTR protein leading to the increase in chloride transmembrane transport and in the reduction of mucus viscosity, they could potentially also interfere with the patomechanism of CRS and thus decrease CRS symptoms in CF. This evidence concerns the gene CFTR and cystic fibrosis.